Portal de Periódicos da CAPES

Reply to: ‘Severe bullous pemphigoid following Covid‐19 vaccination resistant to rituximab and successfully treated with dupilumab’ by Baffa et al.

2023; Wiley; Volume: 37; Issue: 5 Linguagem: Inglês

10.1111/jdv.18893

1468-3083

Lanyu Sun, Cláudia Brazão, Dora Mancha, Luís Soares‐de‐Almeida, Paulo Filipe,

Coagulation, Bradykinin, Polyphosphates, and Angioedema

Journal of the European Academy of Dermatology and VenereologyVolume 37, Issue 5 p. e578-e580 COVID-19 SPECIAL FORUM - LETTER TO THE EDITOR Reply to: 'Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab' by Baffa et al. This article relates to: Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab Maria E. Baffa, Roberto Maglie, Francesca Montefusco, Carlo Pipitò, Stefano Senatore, Emiliano Antiga, Volume 37Issue 2Journal of the European Academy of Dermatology and Venereology pages: e135-e137 First Published online: November 5, 2022 L. Sun, Corresponding Author L. Sun [email protected] orcid.org/0000-0003-2148-1715 Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal Correspondence L. Sun, Av. Prof. Egas Moniz MB, 1649-028 Lisbon, Portugal. Email: [email protected]Search for more papers by this authorC. Brazão, C. Brazão Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, PortugalSearch for more papers by this authorD. Mancha, D. Mancha orcid.org/0000-0002-6536-8936 Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, PortugalSearch for more papers by this authorL. Soares-de-Almeida, L. Soares-de-Almeida orcid.org/0000-0003-4026-6105 Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal Dermatology Universitary Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal Dermatology Research Unit, iMM João Lobo Antunes, Lisbon, PortugalSearch for more papers by this authorP. Filipe, P. Filipe orcid.org/0000-0001-6917-527X Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal Dermatology Universitary Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal Dermatology Research Unit, iMM João Lobo Antunes, Lisbon, PortugalSearch for more papers by this author L. Sun, Corresponding Author L. Sun [email protected] orcid.org/0000-0003-2148-1715 Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal Correspondence L. Sun, Av. Prof. Egas Moniz MB, 1649-028 Lisbon, Portugal. Email: [email protected]Search for more papers by this authorC. Brazão, C. Brazão Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, PortugalSearch for more papers by this authorD. Mancha, D. Mancha orcid.org/0000-0002-6536-8936 Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, PortugalSearch for more papers by this authorL. Soares-de-Almeida, L. Soares-de-Almeida orcid.org/0000-0003-4026-6105 Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal Dermatology Universitary Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal Dermatology Research Unit, iMM João Lobo Antunes, Lisbon, PortugalSearch for more papers by this authorP. Filipe, P. Filipe orcid.org/0000-0001-6917-527X Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal Dermatology Universitary Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal Dermatology Research Unit, iMM João Lobo Antunes, Lisbon, PortugalSearch for more papers by this author First published: 22 January 2023 https://doi.org/10.1111/jdv.18893Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Baffa E, Maglie R, Montefusco F, Pipitò C, Senatore S, Antiga E. Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab. J Eur Acad Dermatol Venereol. 2022; 37: e135–7. PubMedWeb of Science®Google Scholar 2Maronese A, Caproni M, Moltrasio C, Genovese G, Vezzoli P, Sena P, et al. Bullous pemphigoid associated with COVID-19 vaccines: an Italian multicentre study. Front Med. 2022; 28(9):841506. 10.3389/fmed.2022.841506 Web of Science®Google Scholar 3Afacan E, Edek C, İlter N, Gülekon A. Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center. Int J Dermatol. 2022; 61(5): 626–7. 10.1111/ijd.16086 CASPubMedWeb of Science®Google Scholar 4Tomayko M, Damsky W, Fathy R, McMahon E, Turner N, Valentin N, et al. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. J Allergy Clin Immunol. 2021; 148(3): 750–1. 10.1016/j.jaci.2021.06.026 CASPubMedWeb of Science®Google Scholar 5Gambichler T, Hamdani N, Budde H, Sieme M, Skrygan M, Scholl L, et al. Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies. Br J Dermatol. 2022; 186(4): 728–31. 10.1111/bjd.20890 CASPubMedWeb of Science®Google Scholar 6Li N, Culton D, Diaz LA, Liu Z. Modes of action of intravenous immunoglobulin in bullous pemphigoid. J Invest Dermatol. 2018; 138(6): 1249–51. 10.1016/j.jid.2018.02.020 CASPubMedWeb of Science®Google Scholar 7Amagai M, Ikeda S, Hashimoto T, Mizuashi M, Fujisawa A, Ihn H, et al. A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J Dermatol Sci. 2017; 85(2): 77–84. 10.1016/j.jdermsci.2016.11.003 CASPubMedWeb of Science®Google Scholar 8Hoffmann O, Enk H. High-dose intravenous immunoglobulin in skin autoimmune disease. Front Immunol. 2019; 10:1090. 10.3389/fimmu.2019.01090 PubMedWeb of Science®Google Scholar 9Furlan A, Forner G, Cipriani L, Vian E, Rigoli R, Gherlinzoni F, et al. COVID-19 in B cell-depleted patients after rituximab: a diagnostic and therapeutic challenge. Front Immunol. 2021; 12:763412. 10.3389/fimmu.2021.763412 CASPubMedWeb of Science®Google Scholar 10Romero C, Diéz J, Gajardo R. Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products-an update. Lancet Infect Dis. 2022; 22(1): 19. 10.1016/S1473-3099(21)00755-6 CASPubMedWeb of Science®Google Scholar Citing Literature Volume37, Issue5Special issue on melanoma: Immune check point and BRAF‐MEK inhibitors in melanomaMay 2023Pages e578-e580 This article also appears in:JEADV COVID-19 articles ReferencesRelatedInformation